Scott Macdiarmid, MD
Urology · Greensboro, NCNPI 1346222775
Payments from drug & device makers
Across 817 payments — averaging $1079.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Valencia Technologies Corporation$284K
- Laborie Medical Technologies Corp.$144K
- Sumitomo Pharma America, Inc.$99K
- Medtronic$92K
- Urovant Sciences Inc$87K
- Ferring Pharmaceuticals Inc.$63K
- plus $112K from 32 others
Across 4 payments — averaging $1007.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$4K
What the payments were for
- Consulting fees$464,35260%
- Speaking & faculty fees$219,38228%
- Travel & lodging$72,6249%
- Food & beverage$16,1202%
- Education$1,1930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Valencia Technologies Corporation | 141 | $283,923 |
| Laborie Medical Technologies Corp. | 28 | $144,323 |
| Sumitomo Pharma America, Inc. | 85 | $99,252 |
| Medtronic(2 entities) | 78 | $92,157 |
| Urovant Sciences Inc | 93 | $87,288 |
| Ferring Pharmaceuticals Inc. | 137 | $63,319 |
| Astellas Pharma US Inc | 83 | $54,966 |
| Antares Pharma, Inc. | 27 | $33,909 |
| AbbVie(2 entities) | 23 | $10,650 |
| Bayer | 14 | $9,403 |
| Merck | 24 | $474 |
| Johnson & Johnson | 14 | $349 |
| Contura, Inc. | 4 | $287 |
| Pfizer | 16 | $274 |
| Boston Scientific | 2 | $209 |
| Procept Biorobotics Corporation | 1 | $189 |
| Novartis | 5 | $135 |
| Urogen Pharma, Inc. | 4 | $102 |
| SRS Medical Systems, Inc. | 1 | $82 |
| Caldera Medical, Inc | 2 | $73 |
| Dendreon Pharmaceuticals LLC | 3 | $72 |
| Endo Pharmaceuticals Inc. | 5 | $68 |
| E.r. Squibb & Sons, L.L.C. | 5 | $67 |
| Amgen | 3 | $47 |
| AstraZeneca | 2 | $46 |
| Blue Earth Diagnostics | 2 | $38 |
| Coloplast | 2 | $38 |
| Verity Pharmaceuticals Inc. | 2 | $32 |
| Tolmar, Inc. | 1 | $30 |
| Urocure LLC | 1 | $28 |
| Halozyme Inc | 2 | $26 |
| Immunitybio, Inc. | 1 | $23 |
| Palette Life Sciences, Inc. | 1 | $22 |
| Aytu Biopharma, Inc. | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $20 |
| Dornier Medtech America, Inc | 1 | $18 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $15 |
| Myovant Sciences Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- eCoin Device Kit$281,125
- GEMTESA$156,624
- NOCDURNA$85,992
- MYRBETRIQ$53,662
- Urgent PC Neuromodulation System$26,730
- BOTOX$9,263
- Nubeqa$9,179
- INTERSTIM$609
- AquaBeam Robotic System$189
- AMS 700 CXR RTE KIT$133
- ALTAVIVA$133
- Erleada$114
- Bulkamid$101
How this compares
$881,990 in reported general payments places this provider in the 95th percentile of 434 urology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 750 | $518,486 |
| GemtesaVibegron | 579 | $465,847 |
| ElmironPentosan Polysulfate Sodium | 48 | $48,879 |
| Trimethoprim | 750 | $35,527 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 433 | $17,383 |
| NitrofurantoinNitrofurantoin Macrocrystal | 441 | $13,404 |
| Oxybutynin Chloride ErOxybutynin Chloride | 562 | $10,571 |
| Solifenacin Succinate | 328 | $9,245 |
| Cephalexin | 367 | $7,969 |
| Tolterodine Tartrate ErTolterodine Tartrate | 86 | $7,444 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 55 | $6,639 |
| PremarinEstrogens, Conjugated | 11 | $4,846 |
| Tamsulosin Hcl | 339 | $4,699 |
| Estradiol | 49 | $3,227 |
| ToviazFesoterodine Fumarate | 12 | $2,101 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $54,966 | $518,486750 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $99,252 | $465,847579 claims |
| PfizerPremarin, Toviaz | $274 | $6,94723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 urology providers in North Carolina.
Other urology in Greensboro
- John WrennGreensboro$2.9M
- Lester BordenGreensboro$547K
- Theodore MannyGreensboro$88K
- Sigmund TannenbaumGreensboro$20K
- Daniel GeorgeDurham$17.6M
- Robert LippittSmithfield$11.4M
- Thomas PolascikDurham$4.7M
- Judd MoulDurham$4.1M
- Michael KennellyCharlotte$1.4M
- John KasparRaleigh$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.